Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma

EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFR(T790M) and EGFR(C797S). It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibit...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Invest
Главные авторы: Bousquet Mur, Emilie, Bernardo, Sara, Papon, Laura, Mancini, Maicol, Fabbrizio, Eric, Goussard, Marion, Ferrer, Irene, Giry, Anais, Quantin, Xavier, Pujol, Jean-Louis, Calvayrac, Olivier, Moll, Herwig P., Glasson, Yaël, Pirot, Nelly, Turtoi, Andrei, Cañamero, Marta, Wong, Kwok-Kin, Yarden, Yosef, Casanova, Emilio, Soria, Jean-Charles, Colinge, Jacques, Siebel, Christian W., Mazieres, Julien, Favre, Gilles, Paz-Ares, Luis, Maraver, Antonio
Формат: Artigo
Язык:Inglês
Опубликовано: American Society for Clinical Investigation 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994195/
https://ncbi.nlm.nih.gov/pubmed/31671073
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI126896
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы